ME02317B - Neuroprotekcija kod demijelinizacijskih bolesti - Google Patents
Neuroprotekcija kod demijelinizacijskih bolestiInfo
- Publication number
- ME02317B ME02317B MEP-2015-212A MEP21215A ME02317B ME 02317 B ME02317 B ME 02317B ME P21215 A MEP21215 A ME P21215A ME 02317 B ME02317 B ME 02317B
- Authority
- ME
- Montenegro
- Prior art keywords
- combination therapy
- accordance
- dmf
- intended
- interferon
- Prior art date
Links
- 208000016192 Demyelinating disease Diseases 0.000 title claims 2
- 230000004112 neuroprotection Effects 0.000 title 1
- 238000002648 combination therapy Methods 0.000 claims 15
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims 10
- 229960004419 dimethyl fumarate Drugs 0.000 claims 10
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims 7
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims 7
- 229940005650 monomethyl fumarate Drugs 0.000 claims 7
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 6
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 6
- 229960003776 glatiramer acetate Drugs 0.000 claims 6
- 108010005716 Interferon beta-1a Proteins 0.000 claims 4
- 229960004461 interferon beta-1a Drugs 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 108090000467 Interferon-beta Proteins 0.000 claims 3
- 102000003996 Interferon-beta Human genes 0.000 claims 3
- 229960001388 interferon-beta Drugs 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 2
- 206010071068 Clinically isolated syndrome Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 108010005714 Interferon beta-1b Proteins 0.000 claims 1
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960003161 interferon beta-1b Drugs 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Kombinacijska terapija koja se sastoji od (a) dimetil-fumarata (DMF) i/ili monometil-fumarata (MMF) i (b) glatiramer-acetata, naznačena time što je namijenjen upotrebi u liječenju subjekta koji ima multiplu sklerozu (MS).
2. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što na subjektu treba primijeniti 20 mg dnevno glatiramer-acetata.
3. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što na subjektu treba primijeniti manje od 20 mg dnevno glatiramer-acetata.
4. Kombinacijska terapija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što su DMF i/ili MMF i glatiramer-acetat namijenjeni upotrebi u (i) smanjivanju stope recidiva kod subjekta; ili (ii) smanjivanju demijeliniziranje i/ili smrt aksona kod subjekta.
5. Kombinacijska terapija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što su DMF i/ili MMF i glatiramer-acetat formulirani u isti oblik doziranja.
6. Kombinacijska terapija namijenjena upotrebi u skladu s bilo kojim od patentnim zahtjevima 1 do 4, naznačena time što su DMF i/ili MMF i glatiramer-acetat formulirani u odvojene oblike doziranja namijenjene primjeni odvojeno ili zajedno.
7. Kombinacijska terapija koja se sastoji od (a) DMF i/ili MMF i (b) interferona-β, naznačena time što je namijenjena upotrebi u liječenju subjekta koji ima MS.
8. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 7, naznačena time što se interferon-β bira između interferona-β1a i interferona-β1b.
9. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 8, naznačena time što je interferon-β interferon-β1a.
10. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 9, naznačena time što interferon-β1a treba primijeniti u dozi od 5 µg do 80 µg odjednom.
11. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 10, naznačena time što interferon-β1a treba primijeniti jednom tjedno.
12. Kombinacijska terapija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se MS bira između recidivirajući remitirajući MS, sekundarni progresivni MS, primarni progresivni MS, progresivni recidivirajući MS, te klinički izolirani sindrom.
13. Kombinacijska terapija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je spoj koji se bira između DMF, MMF i njihovih kombinacija DMF.
14. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 13, naznačena time što na subjektu treba odjednom primijeniti 240 mg DMF.
15. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 14, naznačena time što DMF na subjektu treba primijeniti dva puta dnevno (BID), što je ekvivalent ukupnoj dnevnoj dozi od 480 mg dnevno.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30432510P | 2010-02-12 | 2010-02-12 | |
| US32148610P | 2010-04-06 | 2010-04-06 | |
| EP11742896.1A EP2533634B1 (en) | 2010-02-12 | 2011-02-11 | Neuroprotection in demyelinating diseases |
| PCT/US2011/024594 WO2011100589A1 (en) | 2010-02-12 | 2011-02-11 | Neuroprotection in demyelinating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02317B true ME02317B (me) | 2016-06-20 |
Family
ID=44368163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-212A ME02317B (me) | 2010-02-12 | 2011-02-11 | Neuroprotekcija kod demijelinizacijskih bolesti |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20130287732A1 (me) |
| EP (2) | EP2533634B1 (me) |
| DK (1) | DK2533634T3 (me) |
| ES (1) | ES2555279T3 (me) |
| HR (1) | HRP20151350T1 (me) |
| HU (1) | HUE025878T2 (me) |
| ME (1) | ME02317B (me) |
| PL (1) | PL2533634T3 (me) |
| PT (1) | PT2533634E (me) |
| RS (1) | RS54551B1 (me) |
| SI (1) | SI2533634T1 (me) |
| SM (1) | SMT201600014B (me) |
| WO (1) | WO2011100589A1 (me) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1663197T1 (sl) | 2003-09-09 | 2008-06-30 | Biogen Idec Internat Gmbh | Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme |
| ES2582942T3 (es) | 2004-10-08 | 2016-09-16 | Forward Pharma A/S | Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico |
| PL2137537T3 (pl) | 2007-02-08 | 2013-10-31 | Biogen Ma Inc | Kompozycje i zastosowania do leczenia stwardnienia rozsianego |
| US20100130607A1 (en) * | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
| EP2379063B2 (en) | 2009-01-09 | 2021-02-24 | Fwp Ip Aps | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| EA201391638A1 (ru) | 2011-06-08 | 2014-05-30 | Байоджен Айдек Ма Инк. | Способ получения высокочистого и кристаллического диметилфумарата |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| KR102105217B1 (ko) * | 2012-02-07 | 2020-06-01 | 바이오젠 엠에이 인코포레이티드 | 다이메틸 푸마레이트를 함유하는 약학 조성물 |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| EP2887933A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| UA119032C2 (uk) * | 2012-10-02 | 2019-04-25 | Женеро Са | Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w |
| EP3566701A1 (en) | 2012-12-21 | 2019-11-13 | Biogen MA Inc. | Deuterium substituted fumarate derivatives |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| JP6373353B2 (ja) | 2013-03-14 | 2018-08-15 | アルカーメス ファーマ アイルランド リミテッド | フマル酸エステルのプロドラッグおよび種々の疾患の治療におけるその使用 |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| WO2015035184A1 (en) | 2013-09-06 | 2015-03-12 | Xenoport, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| WO2015105757A1 (en) * | 2014-01-07 | 2015-07-16 | Biogen Ma Inc. | Dimethyl fumarate for treating multiple sclerosis |
| WO2015127450A1 (en) | 2014-02-24 | 2015-08-27 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| MA40982A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
| MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| FI3506921T3 (fi) | 2016-08-31 | 2023-07-21 | Mapi Pharma Ltd | Glatirameeriasetaattia käsittäviä depot-järjestelmiä |
| MX2019010174A (es) | 2017-03-26 | 2019-10-15 | Mapi Pharma Ltd | Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple. |
| US11382889B2 (en) * | 2018-04-19 | 2022-07-12 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | NRF2 activators for the prevention and/or treatment of axonal degeneration |
| US11446055B1 (en) | 2018-10-18 | 2022-09-20 | Lumoptik, Inc. | Light assisted needle placement system and method |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| EA005005B1 (ru) * | 1998-10-16 | 2004-10-28 | Байоджен, Инк. | ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| ES2582942T3 (es) | 2004-10-08 | 2016-09-16 | Forward Pharma A/S | Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico |
| US20080227847A1 (en) * | 2005-07-07 | 2008-09-18 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
| US20080089861A1 (en) * | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| US20100130607A1 (en) | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
| US20090104142A1 (en) * | 2007-10-17 | 2009-04-23 | Txcell | Compositions for treating multiple sclerosis |
-
2011
- 2011-02-11 PL PL11742896T patent/PL2533634T3/pl unknown
- 2011-02-11 ES ES11742896.1T patent/ES2555279T3/es active Active
- 2011-02-11 ME MEP-2015-212A patent/ME02317B/me unknown
- 2011-02-11 HR HRP20151350TT patent/HRP20151350T1/hr unknown
- 2011-02-11 EP EP11742896.1A patent/EP2533634B1/en not_active Revoked
- 2011-02-11 WO PCT/US2011/024594 patent/WO2011100589A1/en not_active Ceased
- 2011-02-11 HU HUE11742896A patent/HUE025878T2/en unknown
- 2011-02-11 DK DK11742896.1T patent/DK2533634T3/en active
- 2011-02-11 EP EP15184650.8A patent/EP2982371A1/en not_active Withdrawn
- 2011-02-11 SI SI201130693T patent/SI2533634T1/sl unknown
- 2011-02-11 RS RS20160028A patent/RS54551B1/sr unknown
- 2011-02-11 PT PT117428961T patent/PT2533634E/pt unknown
-
2013
- 2013-03-25 US US13/850,240 patent/US20130287732A1/en not_active Abandoned
-
2016
- 2016-01-15 SM SM201600014T patent/SMT201600014B/it unknown
- 2016-03-01 US US15/057,836 patent/US20160250172A1/en not_active Abandoned
-
2017
- 2017-07-07 US US15/644,029 patent/US20180021288A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20151350T1 (hr) | 2016-01-01 |
| PL2533634T3 (pl) | 2016-04-29 |
| EP2533634B1 (en) | 2015-10-21 |
| EP2533634A4 (en) | 2013-07-10 |
| US20160250172A1 (en) | 2016-09-01 |
| SI2533634T1 (sl) | 2016-01-29 |
| SMT201600014B (me) | 2016-02-25 |
| US20130287732A1 (en) | 2013-10-31 |
| PT2533634E (pt) | 2015-12-28 |
| RS54551B1 (sr) | 2016-06-30 |
| HUE025878T2 (en) | 2016-05-30 |
| EP2533634A1 (en) | 2012-12-19 |
| WO2011100589A1 (en) | 2011-08-18 |
| HK1179116A1 (en) | 2013-09-27 |
| DK2533634T3 (en) | 2016-01-25 |
| ES2555279T3 (es) | 2015-12-30 |
| EP2982371A1 (en) | 2016-02-10 |
| US20180021288A1 (en) | 2018-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02317B (me) | Neuroprotekcija kod demijelinizacijskih bolesti | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| ME02282B (me) | Tretman multiple skleroze lakvinimodom | |
| JP2015038135A5 (me) | ||
| JP2017512193A5 (me) | ||
| JP2013231087A5 (me) | ||
| JP2010248207A5 (me) | ||
| MX2010005676A (es) | Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida. | |
| JP2007515469A5 (me) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2022188083A5 (me) | ||
| RU2014127298A (ru) | Применения иммуноконъюгатов, мишенью которых является cd138 | |
| RU2013148779A (ru) | Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| JP2007238598A5 (me) | ||
| JP2020533302A5 (me) | ||
| IL276194B2 (en) | Pharmaceutical compounds or preparations containing them for use in the treatment of pain | |
| IL292770A (en) | Formulations and doses of pegylated uricase | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| JP2022028975A5 (me) | ||
| HRP20241042T1 (hr) | Novi analozi inzulina i njihova upotreba | |
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru | |
| RU2011101771A (ru) | Педиатрические композиции для лечения рассеянного склероза | |
| JP2015504094A5 (me) | ||
| HRP20190211T1 (hr) | Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti |